For the first time in since it’s inception, the Commission has begun a Phase – II investigation into the proposed Sun-Pharmaceuticals-Ranbaxy Merger. The Commission will in all probability order an investigation to be conducted by the Director General.

 

It is pertinent to note that the Commission does not seem to be focused on the consequent fifth largest Pharmaceutical Corporation in the world which would be created as a result of the merger, but rather has chosen to keep it’s focus limited to India on the impact on drug prices ans their availability in the Country. (There are approximately forty six drugs which will be manufactured by both together merged as the single entity.) It goes without saying that this is speculative and the focus could widen considerably as the case progresses.

 

UPDATE:

C.C.I. Invites Public Comments on Sun-Ranbaxy Deal.